Skip to main
RVTY

Revvity Inc (RVTY) Stock Forecast & Price Target

Revvity Inc (RVTY) Analyst Ratings

Based on 11 analyst ratings
Buy
Strong Buy 18%
Buy 45%
Hold 36%
Sell 0%
Strong Sell 0%

Bulls say

Revvity's positive outlook is supported by its strong growth trajectory in both its life sciences and diagnostics segments, highlighted by the transition from TST to IGRA, which is expected to contribute to annual market growth. The company's financial profile has improved significantly through strategic acquisitions such as BioLegend and EUROIMMUN, which bolster its leading positions in reagents and immunodiagnostics, while also enhancing cross-selling opportunities across its portfolio. Additionally, the integration of a high-margin software solution, Signals, contributes recurring revenue and operating leverage, further supporting the company’s higher profitability potential and market penetration strategies.

Bears say

The financial outlook for Revvity appears unfavorable due to significant challenges in its China segment, particularly in Immunodiagnostics, where revenues are projected to decline substantially, potentially falling below 5% of total revenues by 2026. Additionally, broader economic conditions and industry funding cuts are likely to impact customer demand negatively, leading to reduced growth and market share for the company's products and services. Furthermore, macroeconomic factors such as product shortages, transit delays, and labor shortages may disrupt Revvity's supply chain, exacerbating the company's performance issues.

Revvity Inc (RVTY) has been analyzed by 11 analysts, with a consensus rating of Buy. 18% of analysts recommend a Strong Buy, 45% recommend Buy, 36% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Revvity Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Revvity Inc (RVTY) Forecast

Analysts have given Revvity Inc (RVTY) a Buy based on their latest research and market trends.

According to 11 analysts, Revvity Inc (RVTY) has a Buy consensus rating as of Dec 29, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $112.73, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $112.73, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Revvity Inc (RVTY)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.